Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Steven Kossard classified lymphocyte-related hair loss into four patterns, each linked to different types of baldness.

Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.

Tjalma Syndrome is a rare condition in people with lupus, causing fluid buildup and high CA-125 levels, but not due to tumors.

Nivolumab can cause hair loss as a rare side effect.

Anti-angiogenic drugs do not worsen COVID-19 severity in lung cancer patients.

Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

The treatment was not recommended due to limited effectiveness and significant side effects.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Trans-esophageal echocardiography is crucial for accurately diagnosing heart issues in lupus patients.

IGRT resulted in lower acute toxicity for stage III prostate cancer patients.

HOTTIP and miR-10b contribute to glioma therapy resistance by affecting cell behavior, suggesting they could be targets for treatment.

Severe alopecia areata involves higher levels of certain immune cells, which can be normalized with betamethasone.

Immune cells and plasma proteins are linked to hair loss, suggesting new treatment options.

Correct diagnosis and treatment of lupus vasculitis improved the woman's severe symptoms.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Blocking interferon-gamma might help treat various autoimmune diseases.

The boy's severe skin disorder is caused by two new mutations in his TGM1 gene.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Hair follicles produce IL-7, which is essential for certain skin lymphoma cells to survive.

A man's red tattoo caused a skin reaction and hair loss in his beard, which improved after treatment.

Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Kaposi's sarcoma lesions might originate from benign tissue changes.